cabergoline has been researched along with alpha-synuclein in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chau, KY; Cooper, JM; Korlipara, LV; Schapira, AH | 1 |
| Ali, F; Fatima, A; Khan, W; Khanam, S; Naqvi, AH; Naz, F; Siddique, YH; Singh, BR; Smita Jyoti, R | 1 |
2 other study(ies) available for cabergoline and alpha-synuclein
| Article | Year |
|---|---|
Protection against paraquat and A53T alpha-synuclein toxicity by cabergoline is partially mediated by dopamine receptors.
Topics: alpha-Synuclein; Analysis of Variance; Apoptosis; Blotting, Western; Cabergoline; Caspase 3; Cell Line; Enzyme Activation; Ergolines; Glutathione; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Lactate Dehydrogenases; Membrane Potential, Mitochondrial; Paraquat; Parkinsonian Disorders; Reactive Oxygen Species; Receptors, Dopamine D2 | 2009 |
Effect of cabergoline alginate nanocomposite on the transgenic Drosophila melanogaster model of Parkinson's disease.
Topics: Alginates; alpha-Synuclein; Animals; Animals, Genetically Modified; Behavior, Animal; Cabergoline; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drosophila melanogaster; Longevity; Nanocomposites; Oxidative Stress; Parkinson Disease | 2018 |